Clinical Trial Update: A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM) [Phase 1, Phase 2]

View source ↗

Summary

This update reports the termination of a Phase 1/2 trial of TAK-981 in combination with monoclonal antibodies in adults with relapsed or refractory multiple mye…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• TAK-981

Snippet

Sponsor: Takeda | Conditions: Relapsed and/or Refractory Multiple Myeloma (RRMM) | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-10-02